TCF19

Across TCGA pan-cancer cohorts, TCF19 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCF19 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TCF19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TCF19 expression acts as an unfavorable survival marker.

STAD, SARC, and PRAD are the cancer types where TCF19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.164	0.669	.001	18	view →
SARC	DFS	Median	All	0.115	0.613	.002	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TCF19–STAD (OS)

Open the STAD breakdown →